Genetic resilience to amyloid related cognitive decline
- PMID: 27743375
- PMCID: PMC5392179
- DOI: 10.1007/s11682-016-9615-5
Genetic resilience to amyloid related cognitive decline
Abstract
Preclinical Alzheimer's disease (AD) is characterized by amyloid deposition in the absence of overt clinical impairment. There is substantial heterogeneity in the long-term clinical outcomes among amyloid positive individuals, yet limited work has focused on identifying molecular factors driving resilience from amyloid-related cognitive impairment. We apply a recently developed predicted gene expression analysis (PrediXcan) to identify genes that modify the association between baseline amyloid deposition and longitudinal cognitive changes. Participants free of clinical AD (n = 631) were selected from the AD Neuroimaging Initiative (ADNI) who had a baseline positron emission tomography measure of amyloid deposition (quantified as a standard uptake value ratio), longitudinal neuropsychological data, and genetic data. PrediXcan was used to impute gene expression levels across 15 heart and brain tissues. Mixed effect regression models assessed the interaction between predicted gene expression levels and amyloid deposition on longitudinal cognitive outcomes. The predicted gene expression levels for two genes in the coronary artery (CNTLN, PROK1) and two genes in the atrial appendage (PRSS50, PROK1) interacted with amyloid deposition on episodic memory performance. The predicted gene expression levels for two additional genes (TMC4 in the basal ganglia and HMBS in the aorta) interacted with amyloid deposition on executive function performance. Post-hoc analyses provide additional validation of the HMBS and PROK1 effects across two independent subsets of ADNI using two additional metrics of amyloid deposition. These results highlight a subset of unique candidate genes of resilience and provide evidence that cell-cycle regulation, angiogenesis, and heme biosynthesis likely play a role in AD progression.
Keywords: Amyloid; Cognition; Genetics; PET; PrediXcan; Resilience.
Figures
References
-
- Blasko I, Lederer W, Oberbauer H, Walch T, Kemmler G, Hinterhuber H, Humpel C. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement Geriatr Cogn Disord. 2006;21(1):9–15. doi: 10.1159/000089137. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 MH107666/MH/NIMH NIH HHS/United States
- U01 AG024904/AG/NIA NIH HHS/United States
- R01 HL111516/HL/NHLBI NIH HHS/United States
- U54 HD083211/HD/NICHD NIH HHS/United States
- S10 OD023680/OD/NIH HHS/United States
- R01 MH101820/MH/NIMH NIH HHS/United States
- R01 AG034962/AG/NIA NIH HHS/United States
- K12 HD043483/HD/NICHD NIH HHS/United States
- L30 AG048601/AG/NIA NIH HHS/United States
- UL1 RR024975/RR/NCRR NIH HHS/United States
- K01 AG049164/AG/NIA NIH HHS/United States
- UL1 TR002243/TR/NCATS NIH HHS/United States
- K24 AG046373/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
